Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

NanoString Announces Exclusive License of nCounter Diagnostic Assets and Rights to Veracyte
NanoString Announces Exclusive License of nCounter Diagnostic Assets and Rights to Veracyte


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today announced a strategic transaction to exclusively license select

Savara Announces the Appointment of Dr. An van Es-Johansson to Board of Directors
Savara Announces the Appointment of Dr. An van Es-Johansson to Board of Directors


Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the appointment of Dr. An van Es-Johansson, M.D. to its Board of Directors, effective immediately. Dr. van Es-Johansson

Evotec: Einstieg bei Celmatix, aber...
Evotec: Einstieg bei Celmatix, aber...

In einem insgesamt doch eher schwachen Marktumfeld sticht die Aktie des Hamburger Biotechkonzerns Evotec (WKN: 566480) heute positiv heraus. Grund hierfür dürfte eine Ad hoc-Mitteilung von heute

Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference
Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and

Nature Medicine Publication Highlights Use of NanoString’s Hyb & Seq Technology to Perform Rapid Genotypic and Phenotypic Antibiotic Susceptibility Testing
Nature Medicine Publication Highlights Use of NanoString’s Hyb & Seq Technology to Perform Rapid Genotypic and Phenotypic Antibiotic Susceptibility Testing


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research and molecular diagnostic products, today announced the publication of a

Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Singapore for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer
Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Singapore for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its licensing partner Specialised Therapeutics Asia (STA) has received marketing approval of NERLYNX®

CORRECTING and REPLACING Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries
CORRECTING and REPLACING Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries
Last name of Chief Executive Officer of Pierre Fabre Pharmaceuticals in fourth paragraph should read: Lowinski (instead of Lowinsky). The corrected release reads: PUMA BIOTECHNOLOGY AMENDS
Novocure and the AACR Announce 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
Novocure and the AACR Announce 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program


Novocure (NASDAQ: NVCR) and the American Association for Cancer Research (AACR) announce today their 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research program. The program

Morphosys: Noch Schnäppchenpreise?
Morphosys: Noch Schnäppchenpreise?

Aktuell steuert die Morphosys-Aktie (WKN: 663200) auf ein neues Jahreshoch zu. Dieses liegt bei 113,80 Euro und datiert vom August. Sind das aktuell also Schnäppchenpreise?

Q3-Bericht mit Licht und

Morphosys: Noch Schnäppchenpreise?
Morphosys: Noch Schnäppchenpreise?

Aktuell steuert die Morphosys-Aktie (WKN: 663200) auf ein neues Jahreshoch zu. Dieses liegt bei 113,80 Euro und datiert vom August. Sind das aktuell also Schnäppchenpreise?

Q3-Bericht mit Licht und

Novus Therapeutics to Participate in Two Investor Conferences
Novus Therapeutics to Participate in Two Investor Conferences


Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the

EOS imaging RECEIVES U.S. FDA 510(K) CLEARANCE FOR EOSedge™ ITS NEW GENERATION INNOVATIVE IMAGING SYSTEM
EOS imaging RECEIVES U.S. FDA 510(K) CLEARANCE FOR EOSedge™ ITS NEW GENERATION INNOVATIVE IMAGING SYSTEM


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191128005574/en/



EOSedge™ (Photo: Business Wire)




EOS imaging

ChemoCentryx: Nach +300% - wie geht es jetzt weiter?
ChemoCentryx: Nach +300% - wie geht es jetzt weiter?

Kürzlich explodierte die Aktie des US-amerikanischen Biotechunternehmens ChemoCentryx (WKN: A0NBM2) bekanntlich an einem einzigen Handelstag um mehr als +300% (wir berichteten). Grund hierfür waren

Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)


Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that on November 26, 2019, the independent members of the Company's Board of Directors granted Badrul Chowdhury, M.D

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development and Medical

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development and Medical

ICON plc to Present at Evercore ISI 2nd Annual HealthCONx Conference
ICON plc to Present at Evercore ISI 2nd Annual HealthCONx Conference


ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that Mr

Savara’s COO and CMO to Present at the Evercore ISI 2nd Annual HealthCONx Conference
Savara’s COO and CMO to Present at the Evercore ISI 2nd Annual HealthCONx Conference


Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, will be presenting at the Evercore ISI HealthCONx conference on Wednesday, December 4, 2019 at 2:20 PM ET / 11:20 AM PT at the Four

EOS imaging Announces the Upcoming Launch of EOSedge™, Its New Generation Imaging System
EOS imaging Announces the Upcoming Launch of EOSedge™, Its New Generation Imaging System


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191126005639/en/



(Photo: Business Wire)




EOS imaging (Paris:EOSI)

Mountain View Medical Group Signs New In-Network Agreement with Humana
Mountain View Medical Group Signs New In-Network Agreement with Humana


Humana Inc. (NYSE: HUM), a leading health and well-being company, has reached an agreement that provides its members in-network access to Mountain View Medical Group in Colorado Springs.


This

Dexcom Announces Upcoming Conference Presentation
Dexcom Announces Upcoming Conference Presentation


DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conference:




  • Steven Pacelli, Executive Vice President, Strategy

Dexcom Announces Upcoming Conference Presentation
Dexcom Announces Upcoming Conference Presentation


DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conference:




  • Steven Pacelli, Executive Vice President, Strategy

Sangamo Therapeutics Appoints James R. Meyers to Its Board of Directors
Sangamo Therapeutics Appoints James R. Meyers to Its Board of Directors


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of James R. Meyers, an accomplished pharmaceutical executive with three decades of commercial

Agilent Receives Multiple Life Science Industry Awards for Innovation
Agilent Receives Multiple Life Science Industry Awards for Innovation


Agilent Technologies Inc. (NYSE: A) announced today that it has received two Life Science Industry Awards (LSIA) for ‘Most Innovative New Products in 2019’ from BioInformatics Inc. Since 2002, the

Novocure to Participate in the Evercore ISI 2019 HealthCONx Conference
Novocure to Participate in the Evercore ISI 2019 HealthCONx Conference


Novocure (NASDAQ: NVCR) announced today that William Doyle, Novocure’s Executive Chairman, will participate in the Evercore ISI 2019 HealthCONx Conference on December 5, 2019, in Boston. Mr